However, in the clinic, completion of a Phase II clinical trial using anti-CCL2 antibodies in castration-resistant prostate cancer found that treatment neither blocked the signaling axis nor did it reduce tumor burden [190]. The gene discussed is CCL2; the disease is neoplasm.